The World Market for Liquid Biopsy, 2023

The World Market for Liquid Biopsy, 2023

Dramatic changes have occurred in the liquid biopsy market, necessitating a resource to provide perspective on the market opportunity. This new report from Kalorama assesses the Liquid Biopsy Market now and in 2027. The report can be useful for business planning, market share assessment, competitive research, and due diligence for mergers and acquisitions and other partnerships.

Liquid biopsy is gaining acceptance each year. Even through the COVID-19 pandemic, announcements of new liquid biopsy products were made and studies conducted to assess the capability of these tests in clinical diagnostics uses. While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.

This report, The World Liquid Biopsy Market, 2023, from Kalorama Information, contains up-to-date information and useful data points for business planning:

The Market for Liquid Biopsy by Region

• North America
• Europe
• Asia
• Rest of World

The Market for CTC-based Liquid Biopsy

• Growth to 2027

The Market for ctDNA-based Liquid Biopsy

• Growth to 2027

The Market for EV and Exosome-based Liquid Biopsy

• Growth to 2027

The Market for Multi-Analyte-based Liquid Biopsy

• Growth to 2027

The Market for Other Analytes Liquid Biopsy

• Growth to 2027

Liquid Biopsy Market by Type of Cancer

• Breast
• Lung
• Colorectal
• Ovarian
• Prostate
• Pan-Cancer
• Other Cancer

R&D: Selected ctDNA-based Liquid Biopsy Tests in Development

On the Market: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021

On the Market: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

• Early detection and diagnosis / screening
• Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
• Therapy personalization and monitoring – by molecular characterization of a patient’s disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
• Disease monitoring – to observe disease progression, tumor evolution, residual disease, and early detection of recurrence

These applications, increasing acceptance, the use of liquid biopsy in combination with other technologies. This report contains market assessments for these application categories.

In addition, the report profiles key companies in the market, including:

• Adaptive Biotechnologies
• Agena Bioscience, Inc.
• Angle, PLC
• Aspira Women’s Health
• Biocartis Group Nv
• Biocept, Inc.
• Biodesix
• Cellmax Life
• Circulogene
• Diacarta, Inc.
• Epic Sciences
• Epigenomics AG
• Exact Sciences
• Exosome Diagnostics, Inc.
• Foundation Medicine, Inc. (Roche)
• Freenome, Inc.
• Gilupi Gmbh
• Grail (Illumina)
• Guardant Health, Inc.
• Hologic
• Lunglife AI (Formerly Cynvenio Biosystems)
• Menarini-Silicon Biosystems, SPA
• Myriad Genetics, Inc.
• Natera, Inc.
• Neogenomics Laboratories, Inc.
• Oncocyte Corporation
• Oncodna S.A.
• Personal Genome Diagnostics
• Qiagen N.V.
• Cell-Free DNA Technologies
• Ctc Technologies
• Exosome And Mirna Technologies
• Resolution Biosciences (Agilent)
• Roche Diagnostics
• Sysmex-Inostics, Inc.
• Tempus
• Volitionrx